Citius Pharmaceuticals, Inc.

The momentum for this stock is not very good. Citius Pharmaceuticals, Inc. is not very popular among insiders. Citius Pharmaceuticals, Inc. is a mediocre stock to choose.

Citius Pharmaceuticals, Inc. engages in the development and commercialization of therapeutic product...

News

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

PR Newswire Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment...\n more…

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncolo

PR Newswire Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology...\n more…

Citius Pharmaceuticals selloff since spinout an opportunity, says EF Hutton

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Citius Pharmaceuticals GAAP EPS of -$0.06 misses by $0.01

SeekingAlpha.com: All News no summary\n more…

CTXR Stock Earnings: Citius Pharma Meets EPS for Q3 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nCTXR stock results show that Citius Pharma met analyst estimates for earnings per share the third quarter of 2024.\nThe post CTXR Stock...\n more…